Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.37 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106432 | 0.98 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL13792184 | 0.98 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 | |
| SCHEMBL12563384 | 0.95 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL23718057 | 0.94 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL11916119 | 0.88 | SIGMAR1 (0.37) | L3MBTL3L3MBTL1SIGMAR1HRH3 | |
| SCHEMBL117945 | 0.88 | SIGMAR1 (0.41) | L3MBTL3L3MBTL1SIGMAR1 | |
| SCHEMBL12395781 | 0.86 | L3MBTL3 (0.36) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL24854368 | 0.86 | L3MBTL3 (0.36) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL24854007 | 0.86 | L3MBTL3 (0.36) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL24854072 | 0.85 | L3MBTL3 (0.35) | L3MBTL3L3MBTL1MBTD1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | UNIV ROCKEFELLER (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | UNIV ROCKEFELLER (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20220170024-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20070293484-A1 | Thiophene Heteroaryl Amines | SUGEN, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070275951-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | MUELLER STEPHAN G | 2007-11-29 | — | — | US | disclosed |
| US-20070275951-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | MUELLER STEPHAN G | 2007-11-29 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-7279471-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | L3MBTL3 4766/4885L3MBTL1 4589/4885MBTD1 3440/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | L3MBTL3 518/4885L3MBTL1 228/4885MBTD1 2125/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | L3MBTL3 1221/4885L3MBTL1 737/4885MBTD1 3067/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | L3MBTL3 4721/4885L3MBTL1 4648/4885MBTD1 3270/4885 |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | L3MBTL3 2154/4885L3MBTL1 2161/4885MBTD1 1855/4885 |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | LSS, NRDC, SPOUT1 | L3MBTL3 1561/4885L3MBTL1 861/4885MBTD1 2329/4885 |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | ALK, NTRK1, ERBB2 | L3MBTL3 1943/4885L3MBTL1 2746/4885MBTD1 3003/4885 |
| US-20070293484-A1 | Thiophene Heteroaryl Amines | TTK, CHEK2, ABL1 | L3MBTL3 1656/4885L3MBTL1 1997/4885MBTD1 1792/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | L3MBTL3 3561/4885L3MBTL1 3128/4885MBTD1 1835/4885 |
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | KRAS, NRAS, HRAS | L3MBTL3 4752/4885L3MBTL1 4551/4885MBTD1 4383/4885 |
| US-20070275951-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | L3MBTL3 4733/4885L3MBTL1 4467/4885MBTD1 3085/4885 |
| US-20220170024-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | GAA, GBA3, GBA2 | L3MBTL3 1397/4885L3MBTL1 675/4885MBTD1 113/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | L3MBTL3 1628/4885L3MBTL1 1291/4885MBTD1 1462/4885 |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | JAK3, JAK2, JAK1 | L3MBTL3 859/4885L3MBTL1 3047/4885MBTD1 2993/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | L3MBTL3 2209/4885L3MBTL1 2249/4885MBTD1 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.